Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review.

A quantitative systematic review was performed to estimate the accuracy of CA 125 assay in the diagnosis of ovarian tumors. Studies that evaluated CA 125 levels for the diagnosis of ovarian tumors and compared them with paraffin-embedded sections as the diagnostic standard were included. Seventeen studies were analyzed, which included 2374 women. The pooled sensitivity for the diagnosis of borderline tumors or ovarian cancer was 0.80 (I.C. 95% 0.76-0.82) and the specificity was 0.75 (I.C. 95% 0.73-0.77). The diagnostic odds ratio for ovarian cancer and borderline lesions vs. benign lesions was 21.2 (95% C.I., 12-37). Summary receiver operating characteristic curves were constructed due to heterogeneity in the diagnostic odds ratio. For malignant and borderline ovarian tumors vs. benign lesions the area under the curve was 0.8877. A CA 125 level of >or= 35 U/ml is a useful preoperative test for predicting the benign or malignant nature of pelvic masses. The accuracy of CA 125 in the diagnosis of ovarian tumors is high and very important in helping the surgeon to decide what kind of surgery should be performed.

[1]  David Moher,et al.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. , 2003, Clinical chemistry.

[2]  R. Bast,et al.  Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. , 1988, American journal of obstetrics and gynecology.

[3]  Javier Zamora,et al.  Meta-DiSc : a software for meta-analysis of test accuracy data , 2015 .

[4]  K. Sugimura,et al.  Developing an MR imaging strategy for diagnosis of ovarian masses. , 2006, Radiographics : a review publication of the Radiological Society of North America, Inc.

[5]  Pelvic Examination, Tumor Marker Level, and Gray‐Scale and Doppler Sonography in the Prediction of Pelvic Cancer , 1997, Obstetrics and gynecology.

[6]  R. Scully.  Early de novo ovarian cancer and cancer developing in benign ovarian lesions , 1995, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[7]  O. Mogensen,et al.  CA 125 in the diagnosis of pelvic masses. , 1989, European journal of cancer & clinical oncology.

[8]  O. Triolo,et al.  The role of transvaginal ultrasonography and serum CA 125 assay combined with age and hormonal state in the differential diagnosis of pelvic masses. , 2004, European journal of gynaecological oncology.

[9]  M. Duffy,et al.  CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use , 2004, International Journal of Gynecologic Cancer.

[10]  K. Sugimura,et al.  A critical evaluation of transvaginal Doppler studies, transvaginal sonography, magnetic resonance imaging, and CA 125 in detecting ovarian cancer , 1992, Obstetrics and gynecology.

[11]  R. Scully.  Influence of origin of ovarian cancer on efficacy of screening , 2000, The Lancet.

[12]  Douglas G. Altman,et al.  Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta‐Analysis , 2008 .

[13]  H. Ngan,et al.  FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. , 2000, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[14]  R. Bast,et al.  Preoperative Evaluation of Serum CA 125 Levels in Patients With Primary Epithelial Ovarian Cancer , 1986, Obstetrics and gynecology.

[15]  Philipp Dahm,et al.  Evidence-Based Surgery Chirurgie factuelle Users ’ guides to the surgical literature : how to use an article about a diagnostic test , 2001 .

[16]  Gordon H. Guyatt,et al.  Users' Guides to the Medical Literature: III. How to Use an Article About a Diagnostic Test A. Are the Results of the Study Valid? , 1994 .

[17]  R. Bast,et al.  CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. , 1989, Acta oncologica.

[18]  R. Bast,et al.  The CA 125 tumour-associated antigen: a review of the literature. , 1989, Human reproduction.

[19]  P. Kenemans,et al.  Pre‐operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays , 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[20]  J. Schlaerth,et al.  Serum CA 125 Levels in Preoperative Evaluation of Pelvic Masses , 1988, Obstetrics and gynecology.

[21]  I. Thaler,et al.  Differentiating Malignant From Benign Ovarian Tumors With Transvaginal Color Flow Imaging , 1992, Obstetrics and gynecology.

[22]  N. Vlahos,et al.  Color and Pulsed Doppler Sonography, Gray‐Scale Imaging, and Serum CA 125 in the Assessment of Adnexal Disease , 1996, Obstetrics and gynecology.

[23]  N. Erdoğan,et al.  Doppler ultrasound assessment and serum cancer antigen 125 in the diagnosis of ovarian tumors , 2005, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[24]  G. Guyatt,et al.  Users ' Guides to the Medical Literature : III . How to Use an Article About a Diagnostic Test : A . Are the Results of the Study Valid ? , 2022 .

[25]  Frederick Mosteller,et al.  Guidelines for Meta-analyses Evaluating Diagnostic Tests , 1994, Annals of Internal Medicine.

[26]  T. Maggino,et al.  CA-125 serum level in the diagnosis of pelvic masses: comparison with other methods. , 1987, European Journal of Gynaecological Oncology.

[27]  P. Bossuyt,et al.  Empirical evidence of design-related bias in studies of diagnostic tests. , 1999, JAMA.

[28]  J. Alcázar,et al.  Transvaginal color Doppler ultrasonography and CA‐125 in suspicious adnexal masses , 1999, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[29]  R. Bast,et al.  Preoperative Serum Tumor-Associated Antigen Levels in Women With Pelvic Masses , 1990, Obstetrics and gynecology.

[30]  A. Gadducci,et al.  Prospective multicenter study on CA 125 in postmenopausal pelvic masses. , 1994, Gynecologic oncology.

[31]  Alex J. Sutton,et al.  Methods for Meta-Analysis in Medical Research , 2000 .

[32]  Z. Yang,et al.  Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. , 1988 .

[33]  Jonathan J Deeks,et al.  Systematic reviews in health care: Systematic reviews of evaluations of diagnostic and screening tests. , 2001, BMJ.

[34]  Douglas G. Altman,et al.  Practical statistics for medical research , 1990 .

[35]  Douglas G. Altman,et al.  Systematic Reviews in Health Care: Meta-Analysis in Context: Second Edition , 2008 .

[36]  A. Paoletti,et al.  The diagnosis of functional ovarian cysts using transvaginal ultrasound combined with clinical parameters, CA125 determinations, and color Doppler. , 2003, European journal of obstetrics, gynecology, and reproductive biology.